ストックスクリーナーアプリを入手
2.35
1.67%
-0.04
アフターアワーズ：
2.32
-0.03
-1.28%
Oramed Pharmaceuticals Inc (ORMP) 最新ニュース
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Oramed Announces Additional $1M Payment on Tranche A Note By Investing.com - Investing.com South Africa
Oramed Announces Additional $1M Payment on Tranche A Note - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com - MarketBeat
ORAMED PHARMACEUTICALS INC. Refinances with New Securities Purchase Agreement - MarketBeat
Oramed Pharmaceuticals Reinforces Scilex Financial Ties - TipRanks
Scilex Holding extends payment deadline in Oramed agreement - Investing.com India
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire
Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - Marketscreener.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Bought by Murchinson Ltd. - MarketBeat
Oramed signs $11.5 million deal for clinical trial services By Investing.com - Investing.com South Africa
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed - Barchart
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Sidoti Csr Weighs in on Orion Group Holdings, Inc.’s Q3 2024 Earnings (NYSE:ORN) - Defense World
Oral Biologics Market 2024-2031 Industry Size Forecast: Growth - openPR
O'Reilly Automotive, Inc. (NASDAQ:ORLY) Position Raised by E Fund Management Co. Ltd. - MarketBeat
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
Wealthspire Advisors LLC Buys 12 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
OMIC’s Market Whiplash: -10.31% YTD Decline, 69.47% Rise in 30 Days - The InvestChronicle
Ashton Thomas Private Wealth LLC Takes Position in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
O’Reilly Automotive, Inc. (NASDAQ:ORLY) Shares Purchased by Acadian Asset Management LLC - Defense World
Private Advisor Group LLC Has $2.56 Million Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Research Analysts Set Expectations for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Hold” - Defense World
Comprehensive Study of Oral Biologics Market 2024-2031 - openPR
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to "Hold" at StockNews.com - MarketBeat
Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Buy - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.58 - MarketBeat
Future Scope of Oral Biologics Market Overall Study Report - openPR
Oramed Pharmaceuticals (FRA:OJU1) 3-Year EPS without NRI Gr - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Net Income From Continuin - GuruFocus.com
ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q2 2024 - InvestorPlace
Oramed Pharmaceuticals (FRA:OJU1) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) GF Value Rank : 1 (As of Aug. 19, 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) Purchase Of Investment : $-105.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Liabilities-to-Assets : 0.04 (As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Cash Flow from Financing : €1.07 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Revenue : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Enterprise Value : €-51.81 Mil (As of Aug. 18, 2024) - GuruFocus.com
Oramed Pharmaceuticals (FRA:OJU1) Growth Rank : 1 (As of Aug. 18, 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) EPS (Basic) : $0.51 (TTM As of Jun. 2024) - GuruFocus.com
ORMP (Oramed Pharmaceuticals) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):